Kevan Herold

Kevan Herold, MD, is the C.N.H. Long Professor of Immunobiology and Medicine at Yale School of Medicine. His dual appointments in Immunobiology and Endocrinology reflect his translational research focus on autoimmune diabetes mechanisms and therapies. He leads clinical trials evaluating teplizumab, a monoclonal antibody that delays Type 1 diabetes onset, and chairs NIDDK's TrialNet network. His lab investigates beta cell protection, checkpoint inhibitor-induced diabetes, and immune regulation in autoimmune diseases.

Education: Jefferson Medical College (MD 1979), Pennsylvania State University (BS 1977). Fellowship at University of Chicago (1984).

Research: Translational immunology targeting Type 1 diabetes pathogenesis. Key areas include: immune checkpoint therapy effects, beta cell preservation, and genetic risk factors. Recent work explores teplizumab's long-term immune modulation and diabetes reversal via reprogrammed cells.

Clinical Focus: Managing Type 1/2 diabetes, post-cancer therapy autoimmune diabetes, and hypoglycemia. Leads PROTECT trial preserving beta cell function in newly diagnosed patients.

Awards: Not explicitly listed but recognized for teplizumab clinical trial milestones and TrialNet leadership.

Lab & Teams: Herold Lab focuses on immunotherapy development. Collaborates with Ana Perdigoto (Yale Internal Medicine) and Paula Preston-Hurlburt (Yale Immunobiology). Active in Yale's Human and Translational Immunology Program and Cancer Immunology initiatives.